Johannes Ottl - Articles and news items

Efficient HTS in the nanoliter range

Issue 3 2005, Past issues / 22 August 2005 / Dr Johannes Ottl, Laboratory Head, Novartis Pharmaceuticals

The pharmaceutical industry continues to face an ever-changing, increasingly competitive business environment. This makes it imperative for drug discovery and development efforts to incorporate new technologies in order to reduce time-to-market to survive in today’s competitive marketplace. This industry pressure to shorten the R&D process has seen high-throughput screening (HTS) technologies becoming a critical part of the drug discovery process.

Versatile miniaturised HTS

Issue 1 2005, Past issues / 7 March 2005 / Oliver Bruttger, Danielle Folio, Christine Niklaus and Johannes Ottl, Novartis Institute for BioMedical Research, Lead Discovery Center Basel

Research and development for a pharmaceutical company is a difficult and lengthy process. It stretches from the discovery phase to preclinical and clinical development stage, through the drug approval period ultimately to clinical application. The discovery research phase is one of the early key processes. The research starts with target identification and validation. Assays are […]


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...